{'fraction_non_alphanumeric': 0.021321961620469083, 'fraction_numerical': 0.006396588486140725, 'mean_word_length': 5.612676056338028, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A novel form of amyloid deposited at the site of enfuvirtide injection.

Cutaneous amyloidosis represents the extracellular deposition of amphophilic hyaline material, which has characteristic staining properties and a fibrillar ultrastructure. The origins of amyloid are diverse; at least 26 amyloid precursor proteins have been described and six have relevance to the skin. While typically of autologous origin, cutaneous amyloidosis has been rarely associated with deposition of medication within the dermis and subcutis.1 Herein, we present a case of cutaneous amyloidosis at the injection site of the antiretroviral medication, enfuvirtide. A 55 year old female who was seropositive for the human immunodeficiency virus (HIV) presented with large, indurated plaques at the sites of subcutaneous enfuvirtide injections on her arms and abdomen (Figure 1). She reported that the sites became ‘‘hot and red’’ after enfuvirtide injections